

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptajsl1623

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page for STN Seminar Schedule - N. America
NEWS 2 DEC 01 ChemPort single article sales feature unavailable
NEWS 3 JUN 01 CAS REGISTRY Source of Registration (SR) searching
enhanced on STN
NEWS 4 JUN 26 NUTRACEUT and PHARMAML no longer updated
NEWS 5 JUN 29 IMSCOPROFILE now reloaded monthly
NEWS 6 JUN 29 EPFULL adds Simultaneous Left and Right Truncation
(SLART) to AB, MCLM, and TI fields
NEWS 7 JUL 09 PATDPAFULL adds Simultaneous Left and Right
Truncation (SLART) to AB, CLM, MCLM, and TI fields
NEWS 8 JUL 14 USGENE enhances coverage of patent sequence location
(PSL) data
NEWS 9 JUL 27 CA/CAPplus enhanced with new citing references
NEWS 10 JUL 16 GBFULL adds patent backfile data to 1855
NEWS 11 JUL 21 USGENE adds bibliographic and sequence information
NEWS 12 JUL 28 EPFULL adds first-page images and applicant-cited
references
NEWS 13 JUL 28 INPADOCDB and INPAFAMDB add Russian legal status data

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN customer
agreement. This agreement limits use to scientific research. Use
for software development or design, implementation of commercial
gateways, or use of CAS and STN data in the building of commercial
products is prohibited and may result in loss of user privileges
and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 08:42:31 ON 07 AUG 2009

=> b reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.22

0.22

FILE 'REGISTRY' ENTERED AT 08:42:53 ON 07 AUG 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 5 AUG 2009 HIGHEST RN 1173150-47-4
DICTIONARY FILE UPDATES: 5 AUG 2009 HIGHEST RN 1173150-47-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> e fenofibrate/cn

E1	1	FENOFEN M/CN
E2	1	FENOFERIN/CN
E3	1 -->	FENOFIBRATE/CN
E4	1	FENOFIBRATE-FOLIC ACID-VITAMIN B6 MIXT./CN
E5	1	FENOFIBRIC ACID/CN
E6	1	FENOFIBRIC ACID TRIS SALT/CN
E7	1	FENOFIX 120/CN
E8	1	FENOFLURAZOLE/CN
E9	1	FENOFOR B/CN
E10	1	FENOFOR BB/CN
E11	1	FENOFOR BFB/CN
E12	1	FENOFOR BK/CN

=> s e3

L1 1 FENOFIBRATE/CN


=> d l1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
RN 49562-28-9 REGISTRY
ED Entered STN: 16 Nov 1984
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl
ester (CA INDEX NAME)

OTHER NAMES:

CN	Ankebin
CN	Antara
CN	Clorofibrate
CN	Elasterin
CN	Fenobrate
CN	<u>Fenofibrate</u>
CN	Fenogal
CN	Fenotard

CN Isopropyl 2-[p-(p-chlorobenzoyl)phenoxy]-2-methylpropionate
 CN LF 178
 CN Lipanthyl
 CN Lipantil
 CN Lipicard
 CN Lipidil
 CN Lipidil Supra
 CN Lipirex
 CN Lipoclar
 CN Lipofene
 CN Liposit
 CN Lipsin
 CN MeltDose
 CN Nolipax
 CN NSC 281319
 CN Procetofen
 CN Procetofene
 CN Procetoken
 CN Protolipan
 CN Secalip
 CN TriCor
 MF C20 H21 Cl O4
 CI COM
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS,
 BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM,
 CSNB, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSCOSEARCH,
 IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*,
 PHAR, PIRA, PROMT, PS, RTECS*, SYNTHLINE, TOXCENTER, ULIDAT, USAN,
 USPAT2, USPATFULL
 (*File contains numerically searchable property data)
 Other Sources: EINECS**, WHO
 (**Enter CHEMLIST File for up-to-date regulatory information)



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2028 REFERENCES IN FILE CA (1907 TO DATE)
 21 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 2038 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> e voglibose/cn

E1	1	VOGGITE/CN
E2	1	VOGGITE (NA2ZR(CO3) (OH) (PO4) .2H2O) /CN
E3	1	--> VOGLIBOSE/CN
E4	1	VOGLISTAT/CN
E5	1	VOGLITE/CN
E6	1	VOGTITE/CN
E7	1	VOIDOX/CN

E8 1 VOILOKARB/CN
 E9 1 VOK/CN
 E10 1 VOK 71/CN
 E11 1 VOK-60/CN
 E12 1 VOK-63/CN


=> s e3

L2 1 VOGLIBOSE/CN

=> d 12

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
 RN 83480-29-9 REGISTRY
 ED Entered STN: 16 Nov 1984
 CN D-epi-Inositol, 3,4-dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)- (CA INDEX NAME)
 OTHER NAMES:
 CN A 71100
 CN AO 128
 CN Basen
 CN Glustat
 CN N-(1,3-Dihydroxy-2-propyl)valiolamine
 CN Voglibose
 CN Voglistat
 FS STEREOSEARCH
 DR 112653-29-9
 MF C10 H21 N O7
 CI COM
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, CSCHEM, DDFU, DRUGU, EMBASE, IMSCOSEARCH, IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT, IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PROMT, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
 (*File contains numerically searchable property data)

Absolute stereochemistry. Rotation (+).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

320 REFERENCES IN FILE CA (1907 TO DATE)
 6 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
 322 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> b caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	15.28	15.50

FILE 'CAPLUS' ENTERED AT 08:43:25 ON 07 AUG 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Aug 2009 VOL 151 ISS 7
 FILE LAST UPDATED: 6 Aug 2009 (20090806/ED)
 REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
 USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAPLUS family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 22.

```
=> s l1 and l2 and py<=2005
      2039 L1
      322 L2
      26321211 PY<=2005
L3      8 L1 AND L2 AND PY<=2005
```

```
=> d l3 1-8 ibib abs hitstr
```



```
L3  ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER:    2005:1075524  CAPLUS
DOCUMENT NUMBER:     143:367288
TITLE:               Preparation of 1,6-naphthyridine and 1,8-naphthyridine
                      derivatives and their use to treat diabetes and
                      related disorders
INVENTOR(S):         Heurich, Rainer
```

PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
 SOURCE: PCT Int. Appl., 302 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005091857	A2	20051006	WO 2005-US5367	20050224 <--
WO 2005091857	A3	20061005		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-552971P P 20040312
 OTHER SOURCE(S): CASREACT 143:367288; MARPAT 143:367288
 GI



AB The title compds. I and II [R1 = alkyl, alkenyl, alkynyl, aryl, etc.; R2 = NR15R16, S(O)0-2R17, OR17 (wherein R15 = H, alkyl, cycloalkyl, etc.; R16 = alkyl, alkenyl, aryl, etc.; R17 = alkyl, alkenyl, aryl, etc.); R3 = aryl, heteroaryl, cycloalkyl, etc.; R4 = O, S, OR21 (R21 = H, alkyl, cycloalkyl, etc.); R5-R8 = cycloalkyl, aryl, heteroaryl, etc.], useful for the treatment of diabetes and related disorders (no specific biol. data given), were prepared Thus, reacting 7-chloro-5-methyl-1-phenyl-2-phenylamino-1H-[1,8]naphthyridin-4-one with morpholine in dioxane afforded 92% 5-methyl-7-(morpholin-4-yl)-1-phenyl-2-phenylamino-1H-[1,8]naphthyridin-4-one. The pharmaceutical compns. containing the compds. I alone or in combination with other therapeutic agents are disclosed.


IT **49562-28-9**, Fenofibrate **83480-29-9**, Voglibose
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (co-drug; preparation of 1,6-naphthyridine and 1,8-naphthyridine derivs. for treating diabetes and related disorders)
 RN 49562-28-9 CAPLUS
 CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 83480-29-9 CAPLUS

CN D-epi-Inositol, 3,4-dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:823553 CAPLUS

DOCUMENT NUMBER: 143:199940

TITLE: Combination drug containing antihyperlipidemics and α -glucosidase inhibitors

INVENTOR(S): Kanazawa, Hashime; Ishitani, Kouki; Sudo, Katsuichi; Tanimori, Naoto

PATENT ASSIGNEE(S): Grelan Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005074909	A1	20050818	WO 2005-JP1801	20050208 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG


CA 2555316 A1 20050818 CA 2005-2555316 20050208 <--
EP 1714648 A1 20061025 EP 2005-709853 20050208
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK,
BA, HR, IS, YU

US 20070197602 A1 20070823 US 2006-588725 20060808
PRIORITY APPLN. INFO.: JP 2004-32329 A 20040209
WO 2005-JP1801 W 20050208

AB Disclosed is a drug which contains a combination of the active ingredients
comprising at least one remedy for hyperlipemia selected from the group
consisting of fibrate compds. (fenofibrate, bezafibrate, salts thereof,
etc.) and HMG-CoA reductase inhibitors (statin compds. such as
pravastatin, atorvastatin, salts thereof, etc.) with an
 α -glucosidase inhibitor (voglibose, acarbose, etc.). The content of
the α -glucosidase inhibitor may be from 0.001 to 50 parts by weight per
100 parts by weight of the remedy for hyperlipemia. Thus, it is possible to
provide a drug having excellent effects of preventing and/or treating
metabolic syndrome, hyperlipemia, diabetes, diabetic complications, etc.
with little side effect. For example, the effect of combination of
fenofibrate and voglibose was examined in streptozotocin-induced diabetic
rats. Also, a tablet containing fenofibrate 100, voglibose 0.2, lactose 69.2,
fine crystalline cellulose 29.6, magnesium stearate 1 mg was formulated.


IT 49562-28-9, Fenofibrate 83480-29-9, Voglibose
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination drug containing antihyperlipidemics and α -glucosidase
inhibitors)

RN 49562-28-9 CAPLUS
CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl
ester (CA INDEX NAME)



RN 83480-29-9 CAPLUS
CN D-epi-Inositol, 3,4-dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-
C-(hydroxymethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:729537 CAPLUS
 DOCUMENT NUMBER: 143:211920
 TITLE: Preparation of diacylglycerol acyltransferase (DGAT1) inhibitors as anorectics.
 INVENTOR(S): Ogawa, Nobuya; Okuma, Chihiro; Furukawa, Noboru
 PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan; Amgen Sf, LLC
 SOURCE: PCT Int. Appl., 90 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005072740	A2	20050811	WO 2005-JP1643	20050128 <--
WO 2005072740	A3	20051027		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2005209115	A1	20050811	AU 2005-209115	20050128 <--
CA 2554455	A1	20050811	CA 2005-2554455	20050128 <--
EP 1718309	A2	20061108	EP 2005-704403	20050128
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU			
CN 1913899	A	20070214	CN 2005-80003524	20050128
JP 2007519605	T	20070719	JP 2006-524132	20050128
US 20070027093	A1	20070201	US 2006-495095	20060728
KR 2006114376	A	20061106	KR 2006-717527	20060830
IN 2006CN03150	A	20070608	IN 2006-CN3150	20060830
PRIORITY APPLN. INFO.:			JP 2004-24812	A 20040130

US 2004-598037P

P 20040802


WO 2005-JP1643

W 20050128

OTHER SOURCE(S):

CASREACT 143:211920; MARPAT 143:211920

GI



I

AB Claimed are anorectics comprising as active ingredients compds. having DGAT inhibitory activity (DGAT1 inhibitory activity) or a prodrugs or a pharmaceutically acceptable salts thereof. Thus, title compound (I)

(preparation

given) at 10 mg/kg orally in rats gave a 30% reduction in food consumption after 8 h.


IT 49562-28-9, Fenofibrate 83480-29-9, Voglibose

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(coadministration; preparation of diacylglycerol acyltransferase (DGAT1) inhibitors as anorectics)

RN 49562-28-9 CAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 83480-29-9 CAPLUS

CN D-epi-Inositol, 3,4-dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:120729 CAPLUS
DOCUMENT NUMBER: 142:219276
TITLE: Preparation of 5-substituted 2H-pyrazole-3-carboxylic
acid derivatives as agonists for the RUP25 nicotinic
acid receptor for the treatment of dyslipidemia and
related diseases
INVENTOR(S): Semple, Graeme; Gharbaoui, Tawfik; Shin, Young-Jun;
Decaire, Marc; Averbuj, Claudia; Skinner, Philip J.
PATENT ASSIGNEE(S): Arena Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 130 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005011677	A1	20050210	WO 2004-US18389	20040610 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004260636	A1	20050210	AU 2004-260636	20040610 <--
CA 2528834	A1	20050210	CA 2004-2528834	20040610 <--
EP 1633351	A1	20060315	EP 2004-776418	20040610
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
US 20070032537	A1	20070208	US 2006-560332	20060908
PRIORITY APPLN. INFO.:				
			US 2003-478664P	P 20030613
			WO 2004-US18389	W 20040610

OTHER SOURCE(S): MARPAT 142:219276
GI




AB Title compds. [I; W, Y = (substituted) alkylene, alkenylene, alkynylene; X = NR3CO, NR3SO2, NR3, CO, CH(OH), C(NH), O, S, SO, SO2, etc.; R3, R4 = H, (substituted) alkyl, Ph, heteroaryl; Z = H, halo, (substituted) Ph, heteroaryl; R1 = H, OH, halo, alkyl, haloalkyl; R2 = H, alkyl; m, n = 0, 1; with provisos], were prepared Thus, 5-methylthiomethyl-2H-pyrazole-3-carboxylic acid (preparation outlined) showed hRUP25 agonist activity with EC50 = 4.3 μ M.

IT 49562-28-9, Fenofibrate 83480-29-9, Voglibose
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministration; preparation of pyrazolecarboxylates as agonists for the RUP25 nicotinic acid receptor for the treatment of dyslipidemia and related diseases)

RN 49562-28-9 CAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 83480-29-9 CAPLUS

CN D-epi-Inositol, 3,4-dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD

(7 CITINGS)

REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:14212 CAPLUS

DOCUMENT NUMBER: 142:107414

TITLE: Compositions comprising balaglitazone and further antidiabetic compounds

INVENTOR(S): Wassermann, Karsten; Wulff, Erik Max

PATENT ASSIGNEE(S): Novo Nordisk A/S, Den.

SOURCE: PCT Int. Appl., 23 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2005000299	A1	20050106	WO 2004-DK448	20040624 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004250994	A1	20050106	AU 2004-250994	20040624 <--
CA 2530228	A1	20050106	CA 2004-2530228	20040624 <--
EP 1638554	A1	20060329	EP 2004-738945	20040624
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
BR 2004012009	A	20060815	BR 2004-12009	20040624
CN 1826112	A	20060830	CN 2004-80020764	20040624
JP 2007506649	T	20070322	JP 2006-515731	20040624
NZ 544307	A	20081224	NZ 2004-544307	20040624
US 20070010423	A1	20070111	US 2005-561639	20051220
KR 2006105431	A	20061011	KR 2005-724956	20051226
ZA 2006000735	A	20070530	ZA 2006-735	20060125
PRIORITY APPLN. INFO.:			DK 2003-973	A 20030627
			US 2003-483196P	P 20030627
			WO 2004-DK448	W 20040624

AB Methods for the treatment of type 2 diabetes and related conditions comprising the administration of balaglitazone in combination with one or more other antidiabetic compound is provided together with combinations useful in said treatment.


IT 49562-28-9, Fenofibrate 83480-29-9, Voglibose

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(compns. comprising balaglitazone and further antidiabetic compds.)

RN 49562-28-9 CAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 83480-29-9 CAPLUS

CN D-epi-Inositol, 3,4-dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:1124581 CAPLUS

DOCUMENT NUMBER: 142:69181

TITLE: Combination therapy for the treatment of hypertension

INVENTOR(S): Fong, Tung M.; Erond, Ngozi E.; Macneil, Douglas J.; McIntyre, James H.; Van Der Ploeg, Leonardus H. T.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 99 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004110368	A2	20041223	WO 2004-US17090	20040602 <--
WO 2004110368	A3	20060720		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,

AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

EP 1635773 A2 20060322 EP 2004-753832 20040602

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR

US 20060160834 A1 20060720 US 2005-559111 20051202

PRIORITY APPLN. INFO.:

US 2003-476390P P 20030606
 WO 2004-US17090 W 20040602

OTHER SOURCE(S): MARPAT 142:69181

AB The present invention relates to compns. comprising an anti-obesity agent and an anti-hypertensive agent useful for the treatment of hypertension, hypertension associated with obesity, and hypertension-related disorders. The present invention further relates to methods of treating or preventing obesity, and obesity-related disorders, in a subject in need thereof by administering a composition of the present invention. The present invention further provides for pharmaceutical compns., medicaments, and kits useful in carrying out these methods.


IT 49562-28-9, Tricor 83480-29-9, Voglibose

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(combination therapy of hypertension and hypertension-related disorders using antiobesity agent and antihypertensive agent and other agents and antihypertensive agent)

RN 49562-28-9 CAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 83480-29-9 CAPLUS

CN D-epi-Inositol, 3,4-dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:878382 CAPLUS

DOCUMENT NUMBER: 141:350161

TITLE: Preparation of azole compounds as PTP1B inhibitors

INVENTOR(S): Ikemoto, Tomoyuki; Tanaka, Masahiro; Yuno, Takeo;
Sakamoto, Johei; Nakanishi, Hiroyuki; Nakagawa,
Yuichi; Ohta, Takeshi; Sakata, Shohei; Morinaga,
Hisayo

PATENT ASSIGNEE(S): Japan Tobacco Inc., Japan

SOURCE: PCT Int. Appl., 542 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese



FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089918	A1	20041021	WO 2004-JP5119	20040409 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004228565	A1	20041021	AU 2004-228565	20040409 <--
CA 2521830	A1	20041021	CA 2004-2521830	20040409 <--
EP 1553091	A1	20050713	EP 2004-726765	20040409 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
BR 2004009136	A	20060425	BR 2004-9136	20040409
CN 1780823	A	20060531	CN 2004-80009487	20040409
JP 3819415	B2	20060906	JP 2005-505323	20040409
ZA 2005008481	A	20070425	ZA 2005-8481	20040409
JP 2005272476	A	20051006	JP 2005-133755	20050428 <--
US 20060122181	A1	20060608	US 2005-176846	20050707
NO 2005005246	A	20051221	NO 2005-5246	20051108 <--
IN 2005CN02927	A	20070608	IN 2005-CN2927	20051109
PRIORITY APPLN. INFO.:			JP 2003-105267	A 20030409
			JP 2003-157590	A 20030603
			JP 2005-505323	A3 20040409
			WO 2004-JP5119	W 20040409

OTHER SOURCE(S): MARPAT 141:350161

GI



AB Title compds. I [V = N, CH; W = S, O; m = 0-2; R1, R2 = H, alkyl; X = NR4, etc.; R4 = H, alkyl; n = 0-4; p = 0, 1; L = CR20R21, etc.; R20 = H, alkyl, etc.; R21 = H, alkyl, etc.; R = CO2R19, etc.; R19 = H, alkyl; B = aryl, heteroaryl; R3 = H, halo, etc.; Y = O, etc.; s = 0, 1; A = (un)substituted alkylene with cycloalkyl; Z = cycloalkyl, etc.] were prepared For example, O-alkylation of 5-hydroxynicotinic acid Me ester with compound II [Q = Cl], e.g., prepared from 4-bromoacetylbenzoic acid in 5 steps, followed by

saponification

afforded compound II [3-carboxypyridin-5-yloxy] in 44.1% overall yield. In PTP1B (protein tyrosine phosphatase 1B) inhibition assays, the IC50 value of compound II [Q = 3-carboxypyridin-5-yloxy] was 0.28 μ M. Compds. I are claimed useful for the treatment of obesity, diabetes, etc. Formulations are given.


IT 49562-28-9, Fenofibrate 83480-29-9, Voglibose

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(medicaments with; preparation of azole compds. as PTP1B inhibitors for treatment of obesity and diabetes)

RN 49562-28-9 CAPLUS


CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 83480-29-9 CAPLUS

CN D-epi-Inositol, 3,4-dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD
(12 CITINGS)
REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L3 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:333698 CAPLUS
DOCUMENT NUMBER: 140:357333
TITLE: Preparation of aroylhydroxypyrazoles for treatment of
metabolic disorders
INVENTOR(S): Semple, Graeme; Shin, Young Jun
PATENT ASSIGNEE(S): Arena Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2004033431	A2	20040422	WO 2003-US31509	20031002 <--
WO 2004033431	A3	20040729		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003282679	A1	20040504	AU 2003-282679	20031002 <--
PRIORITY APPLN. INFO.:			US 2002-416193P	P 20021004
			US 2002-417120P	P 20021007
			WO 2003-US31509	W 20031002
OTHER SOURCE(S):	MARPAT 140:357333			
GI				




AB Title compds. [I; R1 = alkyl, haloalkyl, cycloalkyl, alkenyl, alkynyl, benzyl, optionally substituted with ≥ 1 halo, OH, cyano, NO₂, haloalkyl, amino, aminoalkyl, aminodialkyl, alkyl, cycloalkyl, alkoxy, phenoxy, alkenyl, alkynyl, haloalkoxy, carboxy, carboalkoxy, alkylcarboxamido, arylcarboxamido, heteroarylcarboxamido, heterocyclic carboxamido, alkylthio, alkylsulfinyl, alkylsulfonyl, haloalkylthio, haloalkylsulfinyl, haloalkylsulfonyl, alkylureyl, arylureyl; R2 = H, alkyl, haloalkyl, cycloalkyl, alkenyl, alkynyl, PhCH₂, Ph, heteroaryl, optionally substituted with ≥ 1 halo, OH, cyano, nitro, haloalkyl, amino, aminoalkyl, aminodialkyl, alkyl, cycloalkyl, alkoxy, phenoxy, alkenyl, alkynyl, haloalkoxy, carboxy, carboalkoxy, alkylcarboxamido, arylcarboxamido, heteroarylcarboxamido, heterocyclic carboxamido, alkylthio, alkylsulfonyl, alkylsulfonyl, haloalkylthio, haloalkylsulfinyl, haloalkylsulfonyl, alkylureyl or arylureyl groups; Ar = (substituted) pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl], were prepared for the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like (no data). Thus, nicotinyl chloride, 2-methyl-5-propyl-2,4-dihydropyrazol-3-one, and Ca(OH)₂ were heated at 90° in dioxane for 2 h. to give (5-hydroxy-1-methyl-3-propyl-1H-pyrazol-4-yl)pyridin-3-ylmethanone. I may be used in combination with other active agents such α -glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme inhibitors, and insulin secretion enhancers.

IT 49562-28-9, Fenofibrate 83480-29-9, Voglibose
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (coadministration; preparation of aroylhydroxypyrazoles for treatment of metabolic disorders)
 RN 49562-28-9 CAPLUS
 CN Propanoic acid, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-, 1-methylethyl ester (CA INDEX NAME)



RN 83480-29-9 CAPLUS
 CN D-epi-Inositol, 3,4-dideoxy-4-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-2-C-(hydroxymethyl)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 08:42:31 ON 07 AUG 2009)

FILE 'REGISTRY' ENTERED AT 08:42:53 ON 07 AUG 2009

E FENOFIBRATE/CN

L1 1 S E3

E VOGLIBOSE/CN

L2 1 S E3

FILE 'CAPLUS' ENTERED AT 08:43:25 ON 07 AUG 2009

L3 8 S L1 AND L2 AND PY<=2005

=> logoff hold

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION

FULL ESTIMATED COST

48.86	64.36
-------	-------

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

-6.56	-6.56
-------	-------

SESSION WILL BE HELD FOR 120 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 08:45:16 ON 07 AUG 2009